
Rebecca Haberman, MD, of NYU Langone Health, highlights precision medicine and potential prevention strategies, two areas of promising psoriatic arthritis research.
Rebecca Haberman, MD, of NYU Langone Health, highlights precision medicine and potential prevention strategies, two areas of promising psoriatic arthritis research.
Although her recent study acknowledges potential differences between White and non-White patients with psoriatic arthritis (PsA), Rebecca Haberman, MD, NYU Langone Health, emphasizes the need for further research to understand what these differences are and why they occur.
Recognizing psoriasis and psoriatic arthritis (PsA) in non-White patients is the first step toward providing more equitable care for those of all backgrounds with PsA, according to Rebecca Haberman, MD, of NYU Langone Health.
Although psoriatic arthritis may be more prevalent in White patients, Rebecca Haberman, MD, of NYU Langone Health, emphasizes that the disease affects those across diverse racial and ethnic backgrounds.
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.